P.GomollnF.CaraC.LunaM.Gonzlez-LamaY.PajaresJ
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
Ann Shippy: It's a little overwhelming to do that
Disclosures: David Marti-Aguado: Nothing to Disclose, Jose Miguel Carot Sierra: Nothing to Disclose, Aida Villalba Ortiz: Nothing to Disclose, Rose Marie Vallejo Vigo: Nothing to Disclose, Carmen Lara Romero: Nothing to Disclose, Marta Martn-Fernndez: Nothing to Disclose, Matias Fernandez Paton: Nothing to Disclose, Clara Alfaro-Cervello: Nothing to Disclose, Ana Crespo: Nothing to Disclose, Elena Coello-Cordoba: Nothing to Disclose, Victor Merino Murgui: Nothing to Disclose, Salvador Benlloch: Nothing to Disclose, Judith Perez-Rojas: Nothing to Disclose, Victor Carlos Puglia Puglia: Nothing to Disclose, Antonio Ferrandez: Nothing to Disclose, Victoria Aguilera: Nothing to Disclose, Cristina Montn: Nothing to Disclose, M Desamparados Escudero: Nothing to Disclose, PALOMA LLUCH GARCIA: Nothing to Disclose, rocio aller: Nothing to Disclose, Manuel Romero-Gmez: Nothing to Disclose, Luis Marti-Bonmati: Nothing to Disclose 1601 EFFECTS OF LUSEOGLIFLOZIN ON MASLD IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A POOLED META-ANALYSIS OF PHASE III CLINICAL TRIALS Takumi Kawaguchi 1 Kenta Murotani 2 Hiromitsu Kajiyama 3 Hitoshi Obara 2 Hironori Yamaguchi 3 Yuko Toyofuku 4 Fumi Kaneko 4 Yutaka Seino 5 Saeko Uchida 3 , 1 Kurume University School of Medicine, 2 Kurume University, 3 Taisho Pharmaceutical Co., Ltd., 4 Kurume University Hospital, 5 Kansai Electric Power Hospital Background: Luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, potentially exerts pleiotropic effects on the liver
